News
FEMY
0.4392
+5.32%
0.0222
Analysts Are Bullish on These Healthcare Stocks: Femasys (FEMY), Context Therapeutics (CNTX)
TipRanks · 1d ago
Femasys COO John Charles Canning files initial beneficial ownership statement
Reuters · 2d ago
Femasys Names John Canning as New Chief Operating Officer
TipRanks · 2d ago
Femasys Appoints John Canning COO
Benzinga · 2d ago
Femasys names John Canning chief operating officer to drive commercial growth
Reuters · 2d ago
Press Release: Femasys Appoints John Canning as Chief Operating Officer to Drive Operational Execution and Advance Commercial Growth
Dow Jones · 2d ago
Femasys Q4 EPS $(0.06) Beats $(0.12) Estimate, Sales $813.387K Miss $1.450M Estimate
Benzinga · 3d ago
Femasys GAAP EPS of -$0.47, revenue of $2.29M
Seeking Alpha · 3d ago
Femasys 2025 sales jump on FemBloc demand
Reuters · 3d ago
*Femasys Expects Current Cash and Cash Equivalents Sufficient to Fund Ops Into 3Q
Dow Jones · 3d ago
*Femasys 2025 Sales $2.29M >FEMY
Dow Jones · 3d ago
Femasys FY25 net loss narrows to $18.6 million; sales rise 40.8% to $2.3 million
Reuters · 3d ago
FEMASYS INC. FY EPS USD -0.47
Reuters · 3d ago
FEMASYS ANNOUNCES FINANCIAL RESULTS FOR YEAR ENDED DECEMBER 31, 2025 AND PROVIDES CORPORATE UPDATE
Reuters · 3d ago
Press Release: Femasys Announces Financial -2-
Dow Jones · 3d ago
Press Release: Femasys Announces Financial Results for Year Ended December 31, 2025 and Provides Corporate Update
Dow Jones · 3d ago
Weekly Report: what happened at FEMY last week (0323-0327)?
Weekly Report · 4d ago
Femasys announces special stockholder meeting; board recommends voting for proposals 1, 2 and 3
Reuters · 03/27 20:47
Femasys files Form 3 initial beneficial ownership statement for Director Kenneth D. Eichenbaum
Reuters · 03/24 22:07
Femasys management to meet virtually with Lake Street
TipRanks · 03/24 15:20
More
Webull provides a variety of real-time FEMY stock news. You can receive the latest news about FEMASYS INC through multiple platforms. This information may help you make smarter investment decisions.
About FEMY
Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.